Mayur M. Amonkar

3.9k total citations
98 papers, 2.6k citations indexed

About

Mayur M. Amonkar is a scholar working on Oncology, Pulmonary and Respiratory Medicine and Pathology and Forensic Medicine. According to data from OpenAlex, Mayur M. Amonkar has authored 98 papers receiving a total of 2.6k indexed citations (citations by other indexed papers that have themselves been cited), including 56 papers in Oncology, 30 papers in Pulmonary and Respiratory Medicine and 22 papers in Pathology and Forensic Medicine. Recurrent topics in Mayur M. Amonkar's work include Genetic factors in colorectal cancer (22 papers), Colorectal Cancer Treatments and Studies (20 papers) and HER2/EGFR in Cancer Research (16 papers). Mayur M. Amonkar is often cited by papers focused on Genetic factors in colorectal cancer (22 papers), Colorectal Cancer Treatments and Studies (20 papers) and HER2/EGFR in Cancer Research (16 papers). Mayur M. Amonkar collaborates with scholars based in United States, United Kingdom and Canada. Mayur M. Amonkar's co-authors include S. Suresh Madhavan, Roy D. Altman, Joyce A. Cramer, Ansgar Hebborn, Suresh Madhavan, Mariam Hassan, Ashish V. Joshi, Douglas D. Glover, Timothy S. Tracy and Khalid M. Kamal and has published in prestigious journals such as Journal of Clinical Oncology, Cancer Research and The Lancet Oncology.

In The Last Decade

Mayur M. Amonkar

93 papers receiving 2.5k citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Mayur M. Amonkar United States	28	1.2k	388	351	347	324	98	2.6k
Judith M. E. Walsh United States	23	1.1k 0.9×	421 1.1×	68 0.2×	215 0.6×	416 1.3×	71	3.0k
Lisa M. Hess United States	24	785 0.6×	796 2.1×	88 0.3×	330 1.0×	144 0.4×	145	2.4k
Rahul Mhaskar United States	23	693 0.6×	190 0.5×	135 0.4×	108 0.3×	225 0.7×	150	2.0k
James A. Kaye United States	38	1.2k 1.0×	937 2.4×	73 0.2×	234 0.7×	476 1.5×	169	5.3k
Ted Wun United States	35	450 0.4×	327 0.8×	97 0.3×	88 0.3×	379 1.2×	114	3.8k
Gary C. Yee United States	24	2.1k 1.8×	515 1.3×	757 2.2×	51 0.1×	185 0.6×	64	3.4k
Scott Chasan-Taber United States	19	246 0.2×	526 1.4×	109 0.3×	236 0.7×	282 0.9×	25	4.3k
Maribel Salas United States	20	612 0.5×	317 0.8×	67 0.2×	295 0.9×	166 0.5×	74	2.9k
Andre Wajda Canada	19	439 0.4×	190 0.5×	118 0.3×	249 0.7×	255 0.8×	24	3.5k
Aruna Kamineni United States	28	1.4k 1.1×	651 1.7×	40 0.1×	79 0.2×	443 1.4×	93	2.6k

Countries citing papers authored by Mayur M. Amonkar

Since Specialization

Citations

This map shows the geographic impact of Mayur M. Amonkar's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Mayur M. Amonkar with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Mayur M. Amonkar more than expected).

Fields of papers citing papers by Mayur M. Amonkar

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Mayur M. Amonkar. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Mayur M. Amonkar. The network helps show where Mayur M. Amonkar may publish in the future.

Co-authorship network of co-authors of Mayur M. Amonkar

This figure shows the co-authorship network connecting the top 25 collaborators of Mayur M. Amonkar. A scholar is included among the top collaborators of Mayur M. Amonkar based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Mayur M. Amonkar. Mayur M. Amonkar is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Young, Kate, et al.. (2024). Cost-effectiveness of pembrolizumab for previously treated MSI-H/dMMR solid tumours in the UK. Journal of Medical Economics. 27(1). 279–291.

Amonkar, Mayur M., et al.. (2023). Clinical outcomes of chemotherapy-based therapies for previously treated advanced colorectal cancer: a systematic literature review and meta-analysis. International Journal of Colorectal Disease. 38(1). 10–10. 2 indexed citations

Maio, Michele, Mayur M. Amonkar, Josephine M. Norquist, et al.. (2022). Health-related quality of life in patients treated with pembrolizumab for microsatellite instability–high/mismatch repair–deficient advanced solid tumours: Results from the KEYNOTE-158 study. European Journal of Cancer. 169. 188–197. 7 indexed citations

O’Malley, David M., Giovanni M. Bariani, Philippe A. Cassier, et al.. (2022). Health-related quality of life with pembrolizumab monotherapy in patients with previously treated advanced microsatellite instability high/mismatch repair deficient endometrial cancer in the KEYNOTE-158 study. Gynecologic Oncology. 166(2). 245–253. 9 indexed citations

André, Thierry, Mayur M. Amonkar, Josephine M. Norquist, et al.. (2021). Health-related quality of life in patients with microsatellite instability-high or mismatch repair deficient metastatic colorectal cancer treated with first-line pembrolizumab versus chemotherapy (KEYNOTE-177): an open-label, randomised, phase 3 trial. The Lancet Oncology. 22(5). 665–677. 135 indexed citations

Eriksson, Jennifer, et al.. (2020). Experience of mismatch repair/microsatellite instability (MMR/MSI) testing among patients with advanced/metastatic colorectal cancer in the US. Current Medical Research and Opinion. 36(8). 1355–1361. 4 indexed citations

André, Thierry, Mayur M. Amonkar, Josephine M. Norquist, et al.. (2020). 396O Health-related quality of life (HRQoL) in patients (pts) treated with pembrolizumab (pembro) vs chemotherapy as first-line treatment in microsatellite instability-high (MSI-H) and/or deficient mismatch repair (dMMR) metastatic colorectal cancer (mCRC): Phase III KEYNOTE-177 study. Annals of Oncology. 31. S409–S409. 6 indexed citations

Eriksson, Jennifer, et al.. (2019). Mismatch Repair/Microsatellite Instability Testing Practices among US Physicians Treating Patients with Advanced/Metastatic Colorectal Cancer. Journal of Clinical Medicine. 8(4). 558–558. 19 indexed citations

Latimer, Nicholas, et al.. (2015). Adjusting for confounding effects of treatment switching in a randomized phase II study of dabrafenib plus trametinib in BRAF V600+ metastatic melanoma. Melanoma Research. 25(6). 528–536. 6 indexed citations

10.

Amonkar, Mayur M., et al.. (2014). COST-UTILITY ANALYSIS OF DABRAFENIB/TRAMETINIB COMBINATION (D+T) FOR BRAFV600 MUTATION-POSITIVE METASTATIC MELANOMA (MM) FROM THE UNITED KINGDOM (UK) NATIONAL HEALTH SERVICE (NHS) PERSPECTIVE. Value in Health. 17(3). A88–A88. 1 indexed citations

11.

Grob, Jean‐Jacques, Mayur M. Amonkar, Salvador Martín‐Algarra, et al.. (2014). Patient perception of the benefit of a BRAF inhibitor in metastatic melanoma: quality-of-life analyses of the BREAK-3 study comparing dabrafenib with dacarbazine. Annals of Oncology. 25(7). 1428–1436. 37 indexed citations

12.

Thabane, Marroon, et al.. (2014). Cost Effectiveness of Trametinib as First-Line (1l) Treatment for Braf V600 Positive Advanced or Metastatic Melanoma — A Canadian Societal Perspective. Value in Health. 17(3). A83–A83. 3 indexed citations

13.

Delea, Thomas E., et al.. (2013). Cost-Effectiveness of Lapatinib plus Letrozole in her2-Positive, Hormone Receptor–Positive Metastatic Breast Cancer in Canada. Current Oncology. 20(5). 371–387. 19 indexed citations

14.

Sherrill, Beth, Angelo Di Leo, Mayur M. Amonkar, et al.. (2010). Quality-of-life and quality-adjusted survival (Q-TWiST) in patients receiving lapatinib in combination with paclitaxel as first-line treatment for metastatic breast cancer. Current Medical Research and Opinion. 26(4). 767–775. 12 indexed citations

15.

Zhou, Xiaolei, David Cella, David Cameron, et al.. (2009). Lapatinib plus capecitabine versus capecitabine alone for HER2+ (ErbB2+) metastatic breast cancer: quality-of-life assessment. Breast Cancer Research and Treatment. 117(3). 577–589. 48 indexed citations

16.

Sherrill, Beth, et al.. (2008). Q-TWiST analysis of lapatinib combined with capecitabine for the treatment of metastatic breast cancer. British Journal of Cancer. 99(5). 711–715. 33 indexed citations

17.

Mucha, Lisa, et al.. (2008). Impact of compliance and persistence with bisphosphonate therapy on health care costs and utilization. Osteoporosis International. 19(10). 1421–1429. 35 indexed citations

18.

Flood, Emuella, Kathleen Beusterien, Mayur M. Amonkar, et al.. (2008). Patient and caregiver perspective on pediatric eosinophilic esophagitis and newly developed symptom questionnaires. Current Medical Research and Opinion. 24(12). 3369–3381. 31 indexed citations

19.

Gold, Deborah T., et al.. (2008). Descriptive analysis of concomitant prescription medication patterns from 1999 to 2004 among US women receiving daily or weekly oral bisphosphonate therapy. Gender Medicine. 5(4). 374–384. 3 indexed citations

20.

Amonkar, Mayur M., Suresh Madhavan, Sidney A. Rosenbluth, Folakemi T. Odedina, & Kenneth J. Simon. (2000). Assessing Managed Care's Role in Promoting Preventive Care. Journal of Community Health. 25(3). 225–240. 3 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact